一种新的GATA1变异p.G229D,导致血小板形成的缺陷
Biying Ding1, Yinqi Mao1, Yang Li1
1Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Thrombosis research
|December 30, 2023
概括
一种新的GATA1变种 (G229D) 导致血小板功能和形成异常,导致出血问题. 这一发现扩大了已知的GATA1相关的血小板疾病.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- GATA1是血液细胞,特别是巨核细胞发育的关键转录因子.
- 截然不同的GATA1变异与宏血小细胞衰减和血小板功能障碍有关.
研究的目的:
- 为了研究新型GATA1变种 (c. 686G>A,p. G229D) 的病理机制.
- 分析这种变体对患有复发性肌肉血液瘤的患者血小板功能的影响.
主要方法:
- 患者血小板的表型分析.
- 流细胞测量用于血小板形成的前凝剂.
- 对血小板功能进行血栓生成试验 (TGT).
- 对于ANO6表达的qPCR和西白斑.
- 光测定细胞内流量.
主要成果:
- 患者表现出轻度的宏血小细胞衰减,血小板颗粒,聚合和整体素αIIbβ3激活受损.
- 与健康对照人群相比,减少了血小板形成和血栓生成.
- 观察到ANO6表达受损和细胞内流.
结论:
- G229D GATA1变体导致一种具有缺陷前凝功能的新型血小板表型.
- 这扩大了与GATA1变异相关的血小板疾病的范围.
相关概念视频
Formation of the Platelet Plug
6.3K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
702
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
702
Structure and Function of Platelets
1.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.2K
GTPases and their Regulation
8.4K
Guanine nucleotide-binding proteins (G-proteins), also known as GTPases, are a superfamily of proteins that regulate many cellular processes, such as cell signaling, vesicular transport, and the regulation of cell shape and motility. Mutation or dysfunction of these proteins can lead to disease. There are around 40,000 known G-proteins that can broadly be classified into two groups ‒ small G-proteins consisting of a single domain and large multi-domain G-proteins.
Large G-proteins,...
Large G-proteins,...
8.4K
Activation and Inactivation of G Proteins
7.2K
Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high...
7.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
526
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
526


